Last Updated: August 9, 2026

Details for Patent: 9,474,752


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,474,752 protect, and when does it expire?

Patent 9,474,752 protects LETAIRIS and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 9,474,752
Title:Method for treating a pulmonary hypertension condition
Abstract:A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
Inventor(s):Michael J. Gerber, Christopher Dufton
Assignee: Gilead Sciences Inc
Application Number:US14/182,208
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,474,752
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

error: insufficient information

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,474,752

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead LETAIRIS ambrisentan TABLET;ORAL 022081-001 Jun 15, 2007 AB RX Yes No ⤷  Start Trial ⤷  Start Trial FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL ⤷  Start Trial
Gilead LETAIRIS ambrisentan TABLET;ORAL 022081-002 Jun 15, 2007 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,474,752

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2101777 ⤷  Start Trial 300813 Netherlands ⤷  Start Trial
European Patent Office 2101777 ⤷  Start Trial PA2016018 Lithuania ⤷  Start Trial
European Patent Office 2101777 ⤷  Start Trial 93081 Luxembourg ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.